Access info on COVID tests, vaccines, visitor policy, hospitalization data, and FAQs.

toggle mobile menu Menu
toggle search menu

Site Navigation



Finn B. Petersen, MD


Doctor of Medicine

St. Luke's Health Partner
St. Luke's Health Partner

These providers work together to achieve patient-centered care, using proven best practices to offer better care to you and your family.


Accepting new patients
By Referral Only

Facilities & Clinics

About Finn B. Petersen


Finn Petersen, MD is medical director of St. Luke's Cancer Institute - Center for Blood Cancer Therapy's Blood and Marrow Transplant program.

He became involved in the first bone marrow transplants (BMT) in Denmark while in medical school, and after medical school orchestrated the first BMT done for acute leukemia in Denmark. After his fellowship, he joined the faculty at the Fred Hutchinson Cancer Research Center in Seattle and rose to the rank of assistant professor. Afterward, Dr. Petersen accepted a position as full professor at the University of Utah. While there he served as medical director and later program director of the Blood and Marrow Transplant Program, which encompassed the University of Utah's and Intermountain Healthcare's adult BMT programs as well as a pediatric BMT program at Primary Children's Medical Center. He later consolidated adult BMT at the Intermountain Healthcare's LDS Hospital, developing an integrated BMT and hematological malignancy program (blood cancer), focusing on acute leukemia care. In 2015, Dr. Petersen was named one of Utah's Health Care Heroes for his work in establishing and growing a hematological malignancy center of excellence within Intermountain Healthcare.

Dr. Petersen is internationally known for his long-standing work focusing on complications related to hematopoietic stem cell transplantation, and is an author and co-author of over 180 peer reviewed scientific publications, books, or book chapters. He is a frequent invited speaker at national and international conferences on topics of infections and treatment-related complications in blood and marrow transplantation and acute leukemia treatment.

  • Medical School

    University of Copenhagen
  • Residency

    University Medical School
  • Fellowship

    University of Washington
  • Gender

  • Languages Spoken



Petersen, F.B., Lynch, M.H.; Clift, R.A.; Appelbaum, F.R., Sanders, J.E.; Bensinger, W.I., Benyunes, M.C., Doney, K., Fefer, A., Martin., P., Storb., R., Sullivan, K.M., Witherspoon, R., Weiden, P., Thomas, E.D., Hansen, J.A.: Buckner, C.D.:
Autologous marrow transplantation for patients with acute myelogenous leukemia in untreated first relapse or in second remission.
J. Clin. Onc. 7: 1353-1360, 1993.

Petersen, F.B. and Bearman, S.I.:
Preparative regimens and their toxicity. In: G. Forman, E.D. Thomas, K. Blume (ed.)
Bone Marrow Transplantation, Blackwell Scientific Publications Inc., Boston, Massachusetts: 79-95; 1994.

Petersen, F.B., Ford, C.D.:
Maximum supportive care, standard conditioning and allogeneic stem cell transplantation for elderly patients with acute myelogenous leukemia.
Curr Opin Oncol 2009;21(S1)7-9.

Ford C.D., Lopansri B.K., Gazdik M.A., Snow G.L., Webb B.J., Konopa K.L., Petersen F.B.:
The clinical impact of vancomycin-resistant Enterococcus colonization and bloodstream infection in patients undergoing autologous transplantation.
Transpl Infect Dis.
2015 Oct;17(5):688-94.

Webb B.J., Brunner A., Ford C.D., Gazdik M.A., Petersen F.B., Hoda D.:
Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
Transpl Infect Dis. 2016, May 23. doi: 10.1111/tid.12550. [Epub ahead of print]


Reviews for Finn B. Petersen

  • These ratings and comments are collected through in-depth care experience surveys administered by Press Ganey Associates on behalf of St. Luke’s. The star ratings include surveys dating from 2018 to present. We've posted the ten most recent patient comments for your reference.